Sep 20, 2005 - 3:24 am
A prospective, randomized clinical trial of physician's choice chemotherapy versus ATP assay-directed chemotherapy in non-surgically debulked, platinum-resistant ovarian cancer was presented by Ian Cree, M.D., Ph.D., Director, Translational Oncology Research Centre, Portsmouth, England at the May, 2005 ASCO meeting in Orlando, Florida. The results were highly suggestive of an effect due to the assay, and the most successful drug regimens used were nearly all developed using the assay. UK results in cancer are always lower than in the US for a variety of reasons. Part of this is probably lead time bias, but data on surgical debulking may be part of the explanation. Patients in the US get a whole lot more surgery along the way than in Germany and England, and it's not sure that it's our chemo which is doing the job or our surgery.
An abstract on chemosensitivity testing from the American Society of Clinical Oncologists Annual Conference in 1998, summarized a paper from a National Cancer Institute study which looked at thirteen different studies that searched into "in vitro" drug sensitivity testing for patients with cancer. It was noted that there were many different cancers represented in these studies, however, it was seen that the chemotherapy response rates went up using "in vitro" testing, as compared to using standard procedures, and patient survival increased using "in vitro" testing, as compared to using standard procedures.